相关实验视频

Updated: Jan 13, 2026

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

在遗传性血管中使用兰德鲁马布:现实世界的结果和对欧洲获取实践的影响

Dagmara Różyk¹, Witold Wrona², Barbara Kucharczyk³

¹Law Office Dagmara Różyk Attorney at Law, 00-127 Warsaw, Poland.

Journal of clinical medicine

|January 10, 2026

概括

现实世界的数据显示,lanadelumab (一种C1抑制剂) 在波兰几乎消除了遗传性血管 (HAE) 发作. 欧洲的报销政策各不相同,尽管已证明有效,但可能会限制一些HAE患者的获得.

科学领域:

免疫学免疫学免疫学
药理学药理学是指药理学的学科.
卫生经济学卫生经济学

背景情况:

兰德鲁马布已被批准用于欧盟的长期HAE预防.
关于lanadelumab的有效性和补偿的现实数据有限.
本研究探讨了波兰的现实结果和欧洲的退款政策.

研究的目的:

介绍波兰lanadelumab的实际临床结果.
为了比较欧洲的lanadelumab退款标准.
评估有效性如何影响访问限制.

主要方法:

在波兰药物计划中对72名HAE患者进行了回顾性分析.
收集有关人口统计,疾病特征和治疗前后攻击频率的数据.
通过医疗技术评估和文献,审查了欧洲退款政策.

主要成果:

兰德鲁马布在6个月内显著减少了HAE发作,从中位数的15到0 (p < 0.001).
77.8%的患者实现了>90%的攻击减少;结果持续了很长时间.
按需药物的使用量从16剂减少到0剂 (p < 0.001);没有不良事件中止.
欧洲的退款标准各不相同,有些基于攻击频率或响应来限制访问.

结论:

波兰现实世界的数据证实了lanadelumab在预防严重的HAE攻击方面具有很高的有效性.
目前的欧洲退款模式可能会限制一些符合条件的HAE患者的入口.
将现实世界的有效性数据纳入政策可以提高HAE患者的访问和结果.

关键词:

遗传性血管功能拉纳德卢马布拉姆是什么意思现实世界的证据.退款是为了补偿.

更多相关视频

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

相关概念视频

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...